Christopher Mcconville BSc, MSc, PhD

Chris completed his Ph.D. in 2008 in the School of Pharmacy at Queens University Belfast. The work involved the development and characterization of a novel rod insert vaginal ring (RIVR) for the delivery of protein-based HIV microbicides. His subsequent postdoctoral position (Oct 2008 to July 2010) was also conducted in the School of Pharmacy at QUB and involved the development and evaluation of novel vaginal ring formulations, polymer blends and solid dosage forms for the delivery of HIV microbicides.

In July 2010 he was appointed as a senior lecturer in pharmaceutics at Curtin University, Perth, Western Australia, where he continued his research on the development of HIV microbicide products, while also focusing on the solubility enhancement of poorly soluble drugs, the development of biodegradable implantable drug delivery devices and the use of microparticles for controlled pulmonary drug delivery. In June 2012 he was appointed senior lecturer in pharmaceutics at the University of Wolverhampton.

In 2015 he was appointed as a Senior Lecturer in Pharmaceutics, Formulation and Drug Delivery at the University of Birmingham. His research is focused on the development of implantable drug delivery devices for the localized treatment of brain tumors, the development of vaginal dosage forms for the treatment of gynecological cancers and the development of micro and nanoparticles for the sustained delivery of chemotherapeutic drugs. He is also researching the development of novel vaginal rings and tablets for use as Multipurpose Prevention Technologies that deliver multiple drugs using a single formulation to prevent unintended pregnancy; HIV and HSV infections.